QUICK Corp.

Equity Bottom-Up

<div>
<p style="text-align: left;"><strong>As of the end of September 2020, 117 programs are in progress. The full-year outlook has been left unchanged</strong></p>
<ul>
<li>
<strong>3Q (cumulative) had sales of JPY3.8bn and OP of JPY1bn<br></strong>FY12/20 3Q (cumulative) non-consolidated results were sales of JPY3.8bn and OP of JPY1bn. FY12/19 is a 6-month settlement due to a change in the accounting period, so it cannot be compared with the same period of the previous year. The company promoted three business strategies utilizing its own drug discovery development platform…</li>
</ul>
</div>

<p>Notes: This is translated from our Japanese report issued on 14 Aug 2020.</p>
<div>
<p style="text-align: left;"><strong>The impact of COVID-19 is minor. Left the full-year plan unchanged for OP of JPY5.3bn or more</strong></p>
</div>
<ul>
<li>
<strong>In 1H, sales of JPY3.1bn and OP of JPY1.2bn<br></strong>Non-consolidated results for 1H FY12/20 were sales of JPY3.1bn and OP of JPY1.2bn. FY12/19 is a 6-month results due to a change in the accounting period, so it cannot be compared with the same period of the previous year. The company is promoting three business strategies utilizing its…</li>
</ul>

Japan

PeptiDream Inc. is a biopharmaceutical company that researches and develops peptide therapeutics to improve the life of patients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00